Holen Sie sich die Stockscreener-App
13.58
0.22%
0.03
Handel nachbörslich:
13.47
-0.11
-0.81%
Schlusskurs vom Vortag:
$13.55
Offen:
$13.5
24-Stunden-Volumen:
231.76K
Relative Volume:
2.95
Marktkapitalisierung:
$196.58M
Einnahmen:
$1.80M
Nettoeinkommen (Verlust:
$-241.36M
KGV:
-2.6523
EPS:
-5.12
Netto-Cashflow:
$-197.90M
1W Leistung:
+3.27%
1M Leistung:
-11.82%
6M Leistung:
-6.41%
1J Leistung:
-64.75%
1-Tages-Spanne:
$13.25
$13.97
1-Wochen-Bereich:
$11.79
$14.12
52-Wochen-Spanne:
$10.80
$39.79
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Firmenname
Inhibrx Biosciences Inc
Sektor
Branche
Telefon
(858) 795-4220
Adresse
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Vergleichen Sie INBX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
13.58 | 196.58M | 1.80M | -241.36M | -197.90M | -5.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-23 | Eingeleitet | JMP Securities | Mkt Perform |
| 2024-01-23 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-09-21 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-09-14 | Eingeleitet | Credit Suisse | Outperform |
| 2020-09-14 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Inhibrx Biosciences Inc Aktie (INBX) Neueste Nachrichten
(INBX) Trading Signals - Stock Traders Daily
Inhibrx reports promising ozekibart trial results - MSN
Inhibrx's SWOT analysis: oncology biotech stock faces pivotal year ahead - MSN
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 - GuruFocus.com
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer - PR Newswire
Inhibrx's Ozekibart Shows Promising 40% Response Rate in Advanced Colorectal Cancer Trial - StockTitan
How to Take Advantage of moves in (INBX) - Stock Traders Daily
Inhibrx Biosciences enters $150M loan facility - MSN
Inhibrx Biosciences, Inc. Announces Loan Agreement with Oxford Finance LLC - Marketscreener.com
Inhibrx Biosciences Announces Loan Agreement with Oxford Finance - StreetInsider.com
Inhibrx Secures $150M Financing Deal to Advance Clinical Programs, Receives $100M Upfront - StockTitan
(INBX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
How To Trade (INBX) - Stock Traders Daily
Inhibrx's SWOT analysis: biotech stock faces pivotal year amid clinical trials - Investing.com India
(INBX) Trading Report - Stock Traders Daily
Inhibrx Biosciences' SWOT analysis: oncology firm's stock faces pivotal year By Investing.com - Investing.com Nigeria
Inhibrx Biosciences' SWOT analysis: oncology firm's stock faces pivotal year - Investing.com
2024’s Busiest Dealmakers: Novartis Laps The Field, While Lilly, Sanofi Keep Busy - News & Insights
Inhibrx Biosciences director Jon Faiz Kayyem buys $1.52m in stock - Investing.com Nigeria
Trend Tracker for (INBX) - Stock Traders Daily
The recent drop in prices must have disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) institutional investors who own 43% of the shares - Yahoo Finance
institutional investors of Inhibrx Biosciences, Inc. (NASDAQ:INBX) must be disappointed after last week's 15% drop - Simply Wall St
Perceptive Advisors LLC Bolsters Stake in Inhibrx Biosciences Inc - GuruFocus.com
Inhibrx Biosciences Inc (INBX) Quarterly 10-Q Report - Quartzy
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - PR Newswire
Inhibrx Biosciences Inc. (INBX) Quarterly 10-Q Report - Quartzy
Wilson Sonsini Knocks Out Claims Against Inhibrx Biosciences in Trade Secrets Verdict - Law.com
Inhibrx Biosciences’ Trade Secret Case - Global Legal Chronicle
Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform - Seeking Alpha
Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation - Financial Times
James Sabry on industry-shaping changes in innovation and deal-making - BioCentury
Long Term Trading Analysis for (INBX) - Stock Traders Daily
Inhibrx Biosciences' SWOT analysis: cash-rich biotech stock faces pivotal year - Investing.com Australia
Inhibrx Biosciences' SWOT analysis: cash-rich biotech stock faces pivotal year By Investing.com - Investing.com South Africa
why ImmunityBio Inc [IBRX] is a Good Choice for Investors After New Price Target of $6.38 - The DBT News
INVX underperforms with a -2.86 decrease in share price - US Post News
You might want to take a look at Imunon Inc (IMNN) now - SETE News
Immuneering Corp [IMRX] Shares Fall Approximately -71.25% Over the Year - Knox Daily
ImmunityBio, Inc. (NASDAQ:IBRX) Shares Purchased by Private Advisor Group LLC - Defense World
Incyte (NASDAQ:INCY) Given “Hold” Rating at Truist Financial - Defense World
Inhibrx, Inc. (NASDAQ:INBX) Short Interest Down 6.9% in August - Defense World
InnovAge (NASDAQ:INNV) Trading Up 4.2% - Defense World
William Hoffman Sells 40,000 Shares of Inari Medical, Inc. (NASDAQ:NARI) Stock - Defense World
INmune Bio, Inc. (NASDAQ:INMB) Sees Large Increase in Short Interest - Defense World
INmune Bio stock remains a Buy with positive data correlation in Alzheimer’s study, says Scotiabank - Investing.com
A review of IMNN’s current quarter earnings predictions - US Post News
Its Stock Has Paid Off Big Time For INmune Bio Inc - SETE News
Inhibrx, Inc. (NASDAQ:INBX) Short Interest Update - MarketBeat
IBRX Stock on the Rise: A Promising Investment - The InvestChronicle
Market Watch: Immuneering Corp (IMRX)’s Noteworthy Drop, Closing at 2.78 - The Dwinnex
Truist downgrades Incyte to "hold" on doubts of near-term prospects - XM
Finanzdaten der Inhibrx Biosciences Inc-Aktie (INBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):